Companion Dx poised to soar around the globe; Medtronic expands stent indications in Europe;

 @FierceMedDev: Spiking costs blunt Covidien's strong sales quarter. News | Follow @FierceMedDev

 @DamianFierce: Dx company LipoScience is going public, targeting a $40M IPO as $LPDX. Report | Follow @DamianFierce

> The global market for companion diagnostics will reach $19.3 billion by 2023, according to an analyst report. More

> Molecular diagnostic outfit Transgenomic has raised another $8.3 million in private placement financing, planning to speed the commercialization of its genetic tests. News

> Medtronic ($MDT) has picked up CE marks for its Complete SE stent, clearing the device for use in the superficial femoral arteries and proximal popliteal arteries. Item

> Stryker ($SYK) executives told investors that the company's pending $764 million buyout of Trauson Holdings is key to its future growth. Article

> Artemis Diagnostics is changing its name to Lightpoint Medical as it moves forward with a molecular imaging technology for cancer surgery. Release

Biotech News

 @FierceBiotech: AstraZeneca kicks tires on respiratory program ditched by J&J. Story | Follow @FierceBiotech

@JohnCFierce: Cowen's Ed Nash is predicting '16 arrival of Sarepta's eteplirsen, with $263M start Question about accelerated OK. Personally I'm doubtful. | Follow @JohnCFierce

@RyanMFierce: IBM touts push into #biotech with bug-busting gel. Should we care yet? Report | Follow @RyanMFierce

> Celsion snags up to $100M Chinese pharma tie-up ahead of PhIII cancer data. Article

> What's in a drug name? Hopefully some Xzitement. News

Pharma News

@FiercePharma: Merrill Lynch high on Bayer: The company made its list of top Euro-stocks, thanks to new drugs/pipeline. More | Follow @FiercePharma

 @AlisonBFierce: Feds OK Novavax's experimental flu vaccine program. News | Follow @AlisonBFierce

> Groups lobby White House as sunshine rule lingers. Report

> Novartis faces probes on Tekturna tactics, Iran sales. News